Australia Live Biotherapeutic Products And Microbiome Cdmo Market Size & Outlook
Australia live biotherapeutic products and microbiome cdmo market, 2018-2030 (US$M)
Related Markets
Australia live biotherapeutic products and microbiome cdmo market highlights
- The Australia live biotherapeutic products and microbiome cdmo market generated a revenue of USD 0.1 million in 2023 and is expected to reach USD 1.7 million by 2030.
- The Australia market is expected to grow at a CAGR of 46.4% from 2024 to 2030.
- In terms of segment, c.difficle was the largest revenue generating application in 2023.
- C.difficle is the most lucrative application segment registering the fastest growth during the forecast period.
Live biotherapeutic products and microbiome cdmo market data book summary
| Market revenue in 2023 | USD 0.1 million |
| Market revenue in 2030 | USD 1.7 million |
| Growth rate | 46.4% (CAGR from 2023 to 2030) |
| Largest segment | C.difficle |
| Fastest growing segment | C.difficle |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | C.difficle, Crohns disease, IBS, Diabetes |
| Key market players worldwide | Carbios SA, Boise Cascade Co, Assembly Biosciences Inc, Wacker Chemie AG, SGS AG, Lonza Group Ltd, Arranta Bio, 4D Pharma, NIZO, Inpac Pharma |
Other key industry trends
- In terms of revenue, Australia accounted for 0.4% of the global live biotherapeutic products and microbiome cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China live biotherapeutic products and microbiome cdmo market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 10.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Live Biotherapeutic Products And Microbiome CDMO Market Scope
Live Biotherapeutic Products And Microbiome CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia live biotherapeutic products and microbiome cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to live biotherapeutic products and microbiome cdmo market will help companies and investors design strategic landscapes.
C.difficle was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Australia live biotherapeutic products and microbiome cdmo market based on c.difficle, crohns disease, ibs, diabetes covering the revenue growth of each sub-segment from 2018 to 2030.
The live biotherapeutic products and microbiome CDMO market in Australia is driven by several factors such as high unmet needs for medication, the rising prevalence of CDIs, growing incidence of hospitalacquired infections, rising demand for CDMOs, and growing number of clinical trials. The country has a high burden of CDIs since 2015.
This factor has led to an increase in the requirements for effective drug products for reducing the disease burden. According to Clostridioides difficile Infection Annual Report 2022 - SA Health in Australian hospitals, the incidence of CDIs has increased. In 2022, a total of 850 Hospital-Identified CDIs (HI-CDIs) were reported, with an aggregate rate of 4.3 per 10,000 bed days.
Approximately 1 in 5 Australians is estimated to be affected by a major sleep disorder. Furthermore, according to Sydney Morning Herald, in July 2023, studies suggest up to 40% of Australians do not get enough sleep.
Reasons to subscribe to Australia live biotherapeutic products and microbiome cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia live biotherapeutic products and microbiome cdmo market databook
-
Our clientele includes a mix of live biotherapeutic products and microbiome cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia live biotherapeutic products and microbiome cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Australia live biotherapeutic products and microbiome cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia live biotherapeutic products and microbiome cdmo market size, by application, 2018-2030 (US$M)
Australia Live Biotherapeutic Products And Microbiome CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
